TY - JOUR T1 - Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1457 LP - 1460 DO - 10.2967/jnumed.120.258434 VL - 62 IS - 10 AU - Minseok Suh AU - Hyung-Jun Im AU - Hyun Gee Ryoo AU - Keon Wook Kang AU - Jae Min Jeong AU - Sneha Prakash AU - Sanjana Ballal AU - Madhav P. Yadav AU - Chandrasekhar Bal AU - Chang Wook Jeong AU - Cheol Kwak AU - Gi Jeong Cheon Y1 - 2021/10/01 UR - http://jnm.snmjournals.org/content/62/10/1457.abstract N2 - 68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging. ER -